News | Heart Failure | June 30, 2020

BioCardia Resumes Cases in the CardiAMP Heart Failure Trial

BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era

BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era

June 30, 2020 —  BioCardia, Inc. announced that the company has resumed cases in the CardiAMP Heart Failure Trial. The first patient procedure completed since elective procedures were paused due to COVID-19 took place at Morton Plant Hospital in Clearwater, Florida this month. New consents have also taken place at additional centers. 

“We are pleased to be able to resume enrollment at several sites for our lead clinical program and look forward to cases taking place in July and August,” said BioCardia CEO Peter Altman, Ph.D. “As study centers resume elective procedures, we are working closely with our clinical partners to implement new FDA recommendations for clinical trials with respect to COVID-19 in order to minimize the impact on our patients, as well as the trial ahead. COVID-19 has been reported to cause heart damage, and some of our clinical investigators are seeing an increased amount of heart damage in patients who have avoided treatment due to fear of COVID-19 exposure. Our cardiac programs have the potential to help address this growing clinical need and are even more important in the current clinical landscape.”

The CardiAMP Heart Failure Trial is studying CardiAMP cell therapy, an autologous bone marrow-derived mononuclear cell formulation designed to stimulate the body’s natural healing response in treating heart failure which develops after a heart attack. The trial is evaluating the cell therapy’s ability to improve patient survival, exercise capacity and quality of life, as well as its safety. The CardiAMP Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively select patients based on cell potency to maximize the probability of patient benefit.

The ongoing multi-center, double-blinded, randomized (3:2), controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide. The national co-principal investigators are Amish Raval, M.D., of the University of Wisconsin and Carl Pepine, M.D., of the University of Florida, Gainesville.

In March 2020, the Data Safety Monitoring Board indicated there were no safety concerns with the CardiAMP study results and recommended that the trial continue, as planned. To date, 75 patients have been enrolled at 25 active centers. The trial is sponsored, in part, by the Maryland Stem Cell Research Foundation and has reimbursement from the Centers for Medicare and Medicaid Services (CMS). 

For more information: www.biocardia.com

Related CardiAMP Heart Failure Trial content:

How Biotechnology is Impacting the Treatment and Prevention of Heart Disease

CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium

BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial

 

Related Content

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosaic pattern with a bronchocentric distribution to the GGO (white arrow, d) involving both central and peripheral lung parenchyma with pleural effusions (black small arrow, d). image courtesy of Radiological Society of North America

Feature | Coronavirus (COVID-19) | June 30, 2020
In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association with prior exposure
Clive Svendsen, Ph.D., director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute, at work in his laboratory. Photo by Cedars-Sinai.

Clive Svendsen, Ph.D., director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute, at work in his laboratory. Photo by Cedars-Sinai.

News | Coronavirus (COVID-19) | June 30, 2020
July 30, 2020 — A...
The FDA has determined chloroquine and hydroxychloroquine are not effective at treating novel coronavirus and revoked its earlier emergency use authorization (EUA) for the drugs to be used in COVID-19 patients. FDA says hydroxychloroquine does not work to treat COVID-19.Getty Images #COVID19 #COVID19update #SARSCoV2

The FDA has determined chloroquine and hydroxychloroquine are not effective at treating novel coronavirus and revoked its earlier emergency use authorization (EUA) for the drugs to be used in COVID-19 patients. Getty Images 

Feature | Coronavirus (COVID-19) | June 15, 2020 | Dave Fornell, Editor
June 15, 2020 — The U.S.
Centricity Cardio Enterprise[1] is an integrated Cardiovascular PACS (CVPACS) and Information System (CVIS) that bridges the gaps between care areas and healthcare information systems. You get a single point of access for patient data, wave forms, images, analysis tools and physician reports – combined with powerful end-to-end management, analytics and workflow tools across the cardiovascular care pathway.
Webinar | Coronavirus (COVID-19) | June 10, 2020
The financial burden of COVID-19 has put tremendous pressure on health systems across the country.
A PCR genetic test nasal swab being taken from a patient to test if they are infected with COVID-19. While used as the primary test to diagnose coronavirus, up to 20 percent of patients will test negative even eight days after infection. Getty Images

A PCR genetic test nasal swab being taken from a patient to test if they are infected with COVID-19. While used as the primary test to diagnose coronavirus, up to 20 percent of patients will test negative even eight days after infection. Getty Images

News | Coronavirus (COVID-19) | June 10, 2020
June 10, 2020 — In a new study, Johns Hopkins researchers found that testing people for...
Russian interventional cardiologist Alexey Pankov in full personal protective equipment (PPE) for a cath lab procedure in Moscow during the COVID-19 era. Right, an image of the COVID-19 virus from the National Institutes of Health (NIH).

Russian interventional cardiologist Alexey Pankov in full personal protective equipment (PPE) for a cath lab procedure in Moscow during the COVID-19 era. Right, an image of the COVID-19 virus from the National Institutes of Health (NIH). Novel coronavirus has turned out to have a sizable amount of cardiovascular involvement.

Feature | Coronavirus (COVID-19) | June 05, 2020 | Dave Fornell, Editor
It was originally thought novel c...
Gallery | Coronavirus (COVID-19) | June 05, 2020 | Dave Fornell, Editor
This photo gallery is designed to show the impact of the...
This is Figure 2 from the article in Radiology: Acute encephalopathy. A 60 year-old-man without history of seizures presenting with convulsion. (A-B) Multifocal areas of FLAIR hyperintensity in the right cerebellum (arrows in A), left anterior cingular cortex and superior frontal gyrus (arrows in B). (C-D) Restricted diffusion in the left anterior cingulate cortex, superior frontal and middle temporal gyrus (arrows in D) and right cerebellum (arrows in E), consistent with cerebellar diaschisis. #COVID19

This is Figure 2 from the article in Radiology: Acute encephalopathy. A 60 year-old-man without history of seizures presenting with convulsion. (A-B) Multifocal areas of FLAIR hyperintensity in the right cerebellum (arrows in A), left anterior cingular cortex and superior frontal gyrus (arrows in B). (C-D) Restricted diffusion in the left anterior cingulate cortex, superior frontal and middle temporal gyrus (arrows in D) and right cerebellum (arrows in E), consistent with cerebellar diaschisis. F) No hemosiderin deposits in gradient echo sequences.

Feature | Coronavirus (COVID-19) | June 02, 2020
June 2, 2020 — Four recent radiology studies, from New York, Italy, Iran and China, show how...
Nuclear Cardiology Optimistic About Return to Pre-COVID-19 Exam Levels. An American Society of Nuclear Cardiology (ASNC) member survey are confident nuclear cardiology volumes will return to pre-pandemic levels. #COVID19 #SARScov2
News | Coronavirus (COVID-19) | June 01, 2020
June 1, 2020 — While acknowledging the challenges their specialty is facing, more than two-thirds of respondents to a